Abilify Shows Promise in ME/CFS Study (Ann McDonald)
- Condition
- ME/CFS
- At worst
- Moderate (mostly housebound)
- Ill for
- 4 years
- Published
- Mar 2021
Summary
Ann McDonald has taken low-dose Abilify (aripiprazole) at 0.5 mg daily since July 2020. She had moderate ME/CFS for four years before starting it and says the drug improved her health dramatically, markedly reducing her sensitivity to sound and light, with no side effects. She was still on the same 0.5 mg daily dose at the time of writing, roughly eight months in, with no indication on the page that the benefit had faded.
What they credit
Credits Other prescription drugs, Low-dose Abilify / aripiprazole.
Similar stories
-
Treatments. Yes, they do exist.
In this follow-up post, Encephalogirl (Michelle) lists an expanded regimen: low-dose naltrexone, low-dose Abilify, guanfacine, about nine months of tenofovir as part of a planned minimum one-year antiviral course, six weeks of low-dose rapamycin at 1mg once…
-
Hyperbaric Oxygen Therapy Turns Mathew's Long COVID / ME/CFS / POTS Around
Mathew developed long COVID with ME/CFS and POTS after a COVID infection in February 2020 and cycled through severe crashes for four years, at times 20 hours a day in bed, despite midodrine, low-dose naltrexone, Abilify and Paxlovid. In late 2023 he…
-
Drugs Get Mathew Most of the Way and Hyperbaric Oxygen Does the Rest
Dr Mathew Robinson, a university professor, developed long COVID with ME/CFS and POTS after infection in February 2020 and spent 20-22 hours a day in bed. Midodrine, low-dose Abilify and low-dose naltrexone under Bateman Horne Center care brought him to…
-
Radical Rest and Beyond
The author of Encephalogirl (who signs as Michelle) treats her ME/CFS-related dysautonomia and POTS with guanfacine and low-dose Abilify (titrated from 0.5mg down to 0.25mg after migraines, then back up to 0.5mg), an increased dose of low-dose naltrexone, a…